The abstract is read at the publisher; the summary is JClub's.
In two large US HIV clinic cohorts (n = 1070), 96% of viremic people with HIV achieved virologic suppression after long-acting cabotegravir/rilpivirine initiation at a 4-week median.
- Why it matters: Long-acting cabotegravir/rilpivirine can help people with adherence challenges, but outcomes after starting while viremic are unclear and may require closer follow-up.
- What they did: The study analyzed virologic outcomes in two large US clinic cohorts, comparing suppression and blips/failure after initiation with and without baseline viremia.
- The result: Blips and failure occurred more often among people initiating with viremia, implying that careful monitoring and treatment optimization are needed for this subgroup.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.